CardioQ update

Deltex Medical Group PLC
03 April 2008

                            Deltex Medical Group plc

 Second hospital in southern Californian group set to implement routine use of
                     CardioQ in patients undergoing surgery

3 April 2008 - Deltex Medical Group plc ('Deltex Medical'), the UK's leading
haemodynamic monitoring company, today announces that implementation of routine
use of the CardioQ(TM) in a southern Californian hospital group has progressed
to the second of its four acute surgical hospitals.

Deltex Medical began working with the hospital group early in 2007 and at the
first hospital to implement routine use of the CardioQ more than a quarter of
all patients having major surgery are being monitored. Usage is growing both
within and across different surgical procedure and at present more than 100
patients every month benefit from the use of the CardioQ to guide fluid delivery
during their operation. It is anticipated that recent changes in physician
reimbursement for use of oesophageal Doppler monitoring will further accelerate
uptake.

Anaesthetists from one of the largest independent anaesthesia groups in the USA
provide services to the group's hospitals and are leading the implementation
project, working in collaboration with surgeons and administrators. This
anaesthetic group provides services to a further eight acute surgical hospitals
in southern California and treats in excess of 50,000 patients each year
undergoing surgery. Roll out into further sites served by the group is being
planned for 2008/09.

Deltex Medical's Chief Executive, Andy Hill commented:

'This project represents our most successful wide-scale implementation to date
and has enabled us to refine our sales and training model substantially and to
tailor it more effectively to the needs of doctors and administrators wishing to
establish routine use of the CardioQ in major surgery.'

For further information, please contact:-

Deltex Medical Group plc                     01243 774 837
Nigel Keen, Chairman                         [e-mail]
Andy Hill, Chief Executive                   [e-mail]
Ewan Phillips, Finance Director              [e-mail]

Gavin Anderson & Company                     0207 554 1400
Deborah Walter                               [e-mail]
Robert Speed                                 [e-mail]

Charles Stanley Securities
Nominated Advisors                           020 7149 6000
Philip Davies                                [e-mail]
Russell Cook                                 [e-mail]


Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to optimise
critically ill patients and those undergoing routine moderate to major surgery
through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been proven to improve the speed and quality of patient
recovery and reduce hospital stay.

There are already around 1,500 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

   •Validated the results of the Monitor against known standards for
    measuring cardiac output, demonstrating that the technology works

   •Proved that the CardioQ works in a wide range of surgical procedures

   •Demonstrated that the Company's technology provides significant health
    and economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.

The SupraQ is an entirely non-invasive device which uses an ultrasound probe
held at the base of the patient's neck to track the flow of blood in the aorta;
it presents the same data as the CardioQ in a similar format and is used for 
taking snapshots or monitoring over short periods.



                      This information is provided by RNS
            The company news service from the London Stock Exchange